Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:43:02 2024-05-28 am EDT			5-day change	1st Jan Change
27.8 ^EUR	-1.66%		-3.02%	-17.34%

May. 28	Bayer, G+FLAS Team Up to Develop Vitamin D-enriched Tomatoes	MT
May. 28	Bayer: initiatives for genome editing in vegetables	CF

BAYER AG : Deutsche Bank reaffirms its Neutral rating

May 14, 2024 at 05:21 am EDT

Analyst Falko Friedrichs from Deutsche Bank research gives the stock a Neutral rating. The target price is unchanged at EUR 29.

Latest news about Bayer AG

Bayer, G+FLAS Team Up to Develop Vitamin D-enriched Tomatoes	May. 28	MT
Bayer: initiatives for genome editing in vegetables	May. 28	CF
Bayer to Set Up a 600 Million Yuan Facility for Enhanced Capacity in China	May. 24	MT
BAYER AG : JP Morgan reiterates its Neutral rating	May. 20	ZD
BAYER AG : UBS remains Neutral	May. 17	ZD
IQ-AI Unit Delivers Software to Insel Gruppe	May. 17	MT
Bayer: elinzanetant data presented at congress	May. 17	CF
Bayer’s Menopause Drug Reduces Hot Flashes in Late-stage Studies	May. 17	MT
Ag inputs sales seen at good level in the US, not as good in South America	May. 16	RE
Bayer to present new data at ASCO	May. 16	CF
Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer	May. 15	CI
BAYER AG : Barclays remains Neutral	May. 15	ZD
Chemical industry sees first rays of hope and becomes more confident for 2024	May. 15	DP
BAYER AG : UBS remains Neutral	May. 15	ZD
Bayer Launches First-in-Human Study of Prostate Cancer Drug Candidate	May. 15	MT
BAYER : As soft as anticipated	May. 14
Global markets live: Apple, Sony, Vodafone, Booking, Walmart...	May. 14
Bayer Plans More Job Cuts in Push for Fewer Bosses -- Update	May. 14	DJ
Transcript : Bayer Aktiengesellschaft, Q1 2024 Earnings Call, May 14, 2024	May. 14
Jefferies rates Bayer a 'Hold' - Target 29 euros	May. 14	DP
BAYER AG : Gets a Neutral rating from JP Morgan	May. 14	ZD
Deutsche Bank Research rates Bayer a 'Hold' - Target 29 euros	May. 14	DP
BAYER AG : Deutsche Bank reaffirms its Neutral rating	May. 14	ZD
CAC40: little movement on the eve of US inflation	May. 14	CF
BAYER AG : Gets a Neutral rating from UBS	May. 14	ZD

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release

Related indices

EURO STOXX 50 , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : As soft as anticipated

May 14, 2024 at 02:12 pm EDT

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am EST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.8 EUR

Average target price

36.9 EUR

Spread / Average Target

+32.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-17.34%	30.16B
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.66%	328B
ABBVIE INC.	+0.24%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	164B
PFIZER, INC.	-1.70%	164B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : Deutsche Bank reaffirms its Neutral rating

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals